Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience

Alice Indini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Lorenza Di Guardo(Fondazione IRCCS Istituto Nazionale dei Tumori), Domenica Lorusso(Agostino Gemelli University Polyclinic), Carolina Cimminiello(Fondazione IRCCS Istituto Nazionale dei Tumori)
Journal of Gynecologic Oncology
January 1, 2019
10.3802/jgo.2019.30.e94
Cited by 59

Related Papers

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780